1. Neonatal exposure to genistein ameliorates high-fat diet-induced non-alcoholic steatohepatitis in rats
- Author
-
Bing Dong, Xubai Qiao, and Chengfei Huang
- Subjects
Male ,medicine.medical_specialty ,Time Factors ,Medicine (miscellaneous) ,Genistein ,Apoptosis ,Rats, Sprague-Dawley ,chemistry.chemical_compound ,Internal medicine ,medicine ,Weaning ,Animals ,Nutrition and Dietetics ,biology ,business.industry ,Body Weight ,Lipid metabolism ,Organ Size ,Isoflavones ,medicine.disease ,Dietary Fats ,Rats ,Fatty Liver ,Fatty acid synthase ,Endocrinology ,chemistry ,Animals, Newborn ,Gene Expression Regulation ,Liver ,Dietary Supplements ,biology.protein ,Hepatocytes ,Female ,Steatohepatitis ,Steatosis ,business - Abstract
Non-alcoholic steatohepatitis (NASH) is becoming a prevalent disease in developing countries with no effective therapy. Isoflavones such as genistein have been shown to prevent NASH in a rat model, but the effects of neonatal exposure to genistein on lipid metabolism have been rarely studied. In the present study, three doses of genistein (30, 300 or 1200 μg/rat per d) were injected (subcutaneously) into neonatal male Sprague–Dawley rats at postnatal days 1–5. After weaning, these rats were allowed free access to a high-fat diet for 6 weeks. The results demonstrate that NASH was induced by high fat feeding in the control rats, whereas genistein-treated rats displayed smaller body weight, and lower hepatic inflammation and steatosis. The mid dose of genistein was most effective. Neonatal exposure to genistein also resulted in a lower incidence of apoptotic cells in the liver. Additionally, neonatal genistein-treated rats showed lower hepatic expression of fatty acid synthase and sterol regulatory element-binding protein-1, but higher expression of PPARα, indicative of lower rates of lipid synthesis and higher rates of β-oxidation. These results indicate that neonatal treatment with genistein has a prolonged effect on hepatic lipid metabolism that is maintained post-weaning, offering a potential approach for the prevention of hepatic steatosis and NASH.
- Published
- 2011